NEW YORK, NY / ACCESSWIRE / August 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Churchill Capital Corp IV (NYSE:CCIV)
Class Period: January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline: August 30, 2021
The complaint alleges that throughout the class period Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Learn about your recoverable losses in CCIV: http://www.kleinstocklaw.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?id=18473&from=1
AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)
Class Period: November 11, 2019 - July 16, 2021
Lead Plaintiff Deadline: September 27, 2021
The complaint alleges that during the class period AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AHCO: https://www.kleinstocklaw.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?id=18473&from=1
Iterum Therapeutics Plc (NASDAQ:ITRM)
Class Period: November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline: October 4, 2021
The ITRM lawsuit alleges Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=18473&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/659460/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CCIV-AHCO-and-ITRM
